Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $11 at SunTrust
August 8, 2019 1:03 PM EDTSunTrust analyst Edward Nash raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $11.00 (from $9.00) while maintaining a Buy rating.
weakness a buying opportunity ahead of MuSK-MG topline in 1st-half of 2020... More
Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 9c
August 7, 2019 5:18 PM EDTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.11, $0.09 better than the analyst estimate of $0.02. Revenue for the quarter came in at $28.8 million versus the consensus estimate of $18.49 million.
We are very pleased with the continued strength of the commercial launch of Firdapse®, the... More
